Recent posts

TypePostAuthorRepliesLast updated
Book pagePublications and Research Notes James Love010 hours 17 min ago
Blog entryWHA68: Statement of HAI/KEI on Follow-up to 2014 HLM on comprehensive review + assessment of prevention and control of NCDs thiru018 hours 55 min ago
Blog entryMay 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic tests thiru06 days 11 hours ago
Blog entryWHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologies thiru01 week 1 day ago
Blog entryKEI TPP Briefing note 2015:1 Compulsory licenses on patents and the 3-step test KEI Staff01 week 4 days ago
Blog entryLetter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs. KEI Staff01 week 5 days ago
Book pageJames Love, Director James Love02 weeks 12 hours ago
Blog entryKEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP) KEI Staff02 weeks 3 days ago
Blog entryWHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EML thiru02 weeks 3 days ago
Blog entryUACT Comments to DHHS on WHA: Agenda Item 13.4 Assessment of Progress in Prevention & Control of NCDs Manon Ress02 weeks 4 days ago
Blog entryKEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data KEI Staff02 weeks 4 days ago
Blog entryKEI Comments to DHHS on WHA68 agenda 11.2, Framework of Engagement with Non-State Actors Claire Cassedy02 weeks 4 days ago
Blog entryKEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and Development James Love02 weeks 4 days ago
Blog entryWHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health? thiru02 weeks 5 days ago
Book pageFunding James Love02 weeks 6 days ago
Blog entryLetter from KEI to USPTO regarding implementation of Beijing Treaty Manon Ress02 weeks 6 days ago
Blog entryNIH refuses to give information about principals in company seeking exclusive license to HCV patents KEI Staff03 weeks 10 hours ago
Blog entryUSTR's 2015 Special 301 List James Love03 weeks 5 days ago
PageThe USTR Special 301 Reports, 1989 to 2014 Anonymous dude or dudess03 weeks 5 days ago
Blog entry30 April 2015, KEI Seminar on Drug Pricing: Paul Grootendorst on Canadian Drug Pricing Claire Cassedy03 weeks 5 days ago
Blog entryCalifornia AB 463 (Pharmacetical Cost Transparency Act of 2015) Held Over as Two-Year Bill Andrew Goldman03 weeks 6 days ago
Blog entryKassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidies KEI Staff03 weeks 6 days ago
Blog entryPublic Citizen, National Physicians Alliance, Other Civil Society Groups Write Letters in Support of California AB 463 Andrew Goldman04 weeks 5 days ago
Blog entryKEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricing Claire Cassedy04 weeks 6 days ago
Blog entryKEI Notes on California Assembly Health Committee Markup on AB 463 Pharmaceutical Cost Transparency Act of 2015 Andrew Goldman04 weeks 6 days ago